Allogene Therapeutics Inc

NASDAQ: ALLO
$2.11
+$0.06 (+2.9%)
Closing Price on November 21, 2024

ALLO Stock Chart and Intraday Price

ALLO Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 831.29M USD
Shares Outstanding 168,277,000
Allogene Therapeutics Inc is at the forefront of developing innovative cancer treatments. Focused on immuno-oncology, this company is working on creating genetically engineered allogeneic T cell therapies. Its pipeline includes promising candidates like UCART19 for B-cell ALL and ALLO-501 for non-Hodgkin lymphoma, among others targeting various cancers. With strategic collaborations, including with Pfizer and The University of Texas MD Anderson Cancer Center, Allogene aims to revolutionize cancer treatment. Founded in 2017, its headquarters are in South San Francisco, California.

ALLO Articles

3 Hot Penny Stocks to Buy With $1000
Penny stocks are some of my favorite stocks to watch. When these young budding companies release news, their stock prices can make tremendous moves. Of course, if the news is positive, those moves...
Joshua Rodriguez
Published:

Insider Buying of These 6 Stocks Surges: Fracking, Boats, a Buyout Candidate
With the earnings season winding down and windows for making insider purchases opening up, insiders have been scooping up shares of these six stocks.
Trey Thoelcke
Published:

Goldman Sachs Has 5 Stellar Stocks to Buy Under $10 With Up to 735% Upside Potential
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
Lee Jackson
Published:

Monday's Top Analyst Upgrades and Downgrades: Analog Devices, Baxter, Best Buy, Coinbase, Johnson Controls, Lam Research, Micron Technology, Qualcomm and More
Monday's top analyst upgrades and downgrades included Accenture, Analog Devices, Baxter International, Best Buy, Coinbase Global, Johnson Controls, Lam Research, Micron Technology and Qualcomm.
Chris Lange
Published:

Thursday's Top Analyst Upgrades and Downgrades: Carvana, CrowdStrike, Foot Locker, Rivian, Shopify, UnitedHealth and More
Thursday's top analyst upgrades and downgrades included AppLovin, Carvana, CrowdStrike, DocuSign, Fisker, Foot Locker, Intuitive Surgical, Rivian Automotive, Shopify, UnitedHealth, Workday and XPO...
Lee Jackson
Published:

More Problems More Spending: Analysts Upgrade or Downgrade CSX, Qualcomm and More
Friday's additional top analyst upgrades and downgrades included Allogene Therapeutics, CSX, Norfolk Southern, Qualcomm, Toyota and Yelp.
Chris Lange
Published:

Cathie Wood's ARK Invest Buys Over 1.5 Million Shares of Allogene
One of Cathie Wood's ARK Invest exchange-traded funds bought over 1.5 million shares of Allogene on December 14.
Chris Lange
Published:

Friday's Top Analyst Upgrades and Downgrades: Caesars, Charter, Corning, GE, Home Depot, Plug Power, 3M and More
Friday's top analyst upgrades and downgrades included Caesars Entertainment, Charter Communications, Conagra Brands, Corning, Denny’s, General Electric, Home Depot, Plug Power, Sirius XM, 3M and...
Lee Jackson
Published:

Monday's Top Analyst Upgrades and Downgrades: Accenture, Arcturus, Elastic, Marathon, Riot Blockchain, ResMed, Sykes Enterprises, Western Alliance Bancorp and More
Monday’s top analyst upgrades and downgrades included Accenture, Arcturus, Elastic, Marathon, Riot Blockchain, ResMed, Sykes Enterprises, Western Alliance Bancorp and more.
Chris Lange
Published: